Register Now: IKRIS Breast Cancer Awareness Run 2022
Cancer Medicine

Dostralimab: Cancer vanishing drug for the first time in history

  • June 13, 2022
  • 2 mins read

The drug Dostarlimab can become a miracle medicine for cancer patients. In a recent small clinical trial, for the first time in history, it has been found that every single rectal cancer patient who received an experimental treatment found their cancer had vanished. According to the New York Times, in a very small clinical trial, 18 patients took a drug called Dostarlimab for around six months, and in the end, every one of them saw their tumours disappear.

Dostarlimab is a drug with laboratory-produced molecules that act as substitute antibodies in the human body. All 18 rectal cancer patients were given the same drug. As a result of the treatment, cancer was completely obliterated in every patient – undetectable by physical exam, endoscopy, positron emission tomography or PET scans or MRI scans. As per New York Times, the patients involved in the clinical trial faced gruelling previous treatments to obliterate their cancer, such as chemotherapy, radiation and invasive surgery that could result in the bowel, urinary and even sexual dysfunction. The 18 patients went into the trial expecting to go through these as the next step. However, to their surprise, they do not need any further treatment.

Dostralimab: An FDA-approved drug

Dostralimab is also used in treating adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC). The active ingredient in the medicine is Dostralimab with inactive ingredients citric acid monohydrate, L-arginine hydrochloride, polysorbate 80, sodium chloride, trisodium citrate dihydrate, and Water for Injection. Dostralimab injection is a sterile, clear to slightly opalescent, colourless to yellow solution essentially free from visible particles. The drug Dostarlimab is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response. This drug is supplied in the standard strength of 500 mg/10 mL (50 mg/mL) solution.


For the trial, patients took Dostarlimab every three weeks for six months. They were all in similar stages of their cancer – it was locally advanced in the rectum but had not spread to other organs.
The cancer researchers who reviewed the drug told the media outlet that the treatment looks promising, but a larger trial is needed to see if it will work for more patients and if the cancers are truly in remission.

Reference link: